What's Hot

    The bond market is already mountaineering charges as Kevin Warsh takes over as Fed’s new chair | Invesloan.com

    May 14, 2026

    Supreme Court leaves telehealth abortion capsule entry intact for now | Invesloan.com

    May 14, 2026

    OpenAI’s Codex on Mobile Is Good News for Open-Laptop Walkers | Invesloan.com

    May 14, 2026
    Facebook Twitter Instagram
    Finance Pro
    Facebook Twitter Instagram
    invesloan.cominvesloan.com
    Subscribe for Alerts
    • Home
    • News
    • Politics
    • Money
    • Personal Finance
    • Business
    • Economy
    • Investing
    • Markets
      • Stocks
      • Futures & Commodities
      • Crypto
      • Forex
    • Technology
    invesloan.cominvesloan.com
    Home » Trump indicators government order directing FDA to evaluation psychedelics, cites veterans | Invesloan.com
    Politics

    Trump indicators government order directing FDA to evaluation psychedelics, cites veterans | Invesloan.com

    April 18, 2026Updated:April 18, 2026
    Share
    Facebook Twitter LinkedIn Pinterest Email

    NEWYou can now listen to Fox News articles!

    President Donald Trump signed an executive order Saturday that he said “directs the FDA to expedite their review of certain psychedelics already designated as breakthrough therapy drugs.”

    “The executive order I’m signing, we’re actually signing the executive order today, is really a moment,” Trump said. “These treatments are currently in the advanced stages of clinical trials to ensure that they’re both safe and effective for the American patients.”

    The president said the executive order would implement “historic reforms to dramatically accelerate access to new medical research and treatments based on psychedelic drugs.” 

    “In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans,” Trump said, citing the veteran suicide rate.

    President Donald Trump signing an executive order

    President Donald Trump speaks before signing an executive order in the Oval Office of the White House, on Saturday, April 18, 2026, in Washington. (Julia Demaree Nikhinson/AP)

    “And the nice part is we’re actually doing this early, but it has been going on. Research has been going on for quite some time. But, you know, usually with things like this, nothing ever happens, no matter how the research ends up, but we’re changing that. This order will clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA and the Department of Veterans Affairs, and facilitate fast rescheduling of any psychedelic drugs that become FDA approved,” Trump continued.

    The president said “in 2024, a study from Stanford University, 30 special operation veterans with traumatic brain injuries underwent — it’s called ibogaine treatment — ibogaine, remember the name,” noting that they “experienced an 80 to 90% reduction in symptoms of depression and anxiety within one month.”

    “In Texas, Republican leaders have already committed $50 million to the ibogaine research. And today, the federal government is making a $50 million research investment in its own. And so that was just approved just last night,” Trump announced.

    “We’re also opening a pathway for ibogaine to be administered to desperately ill patients under the right to try law,” Trump said.

    “Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life, just lead a happier life,” he added.

    This is a developing story. Please check back for updates.

    Greg Norman is a reporter at Fox News Digital.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Keep Reading

    Supreme Court leaves telehealth abortion capsule entry intact for now | Invesloan.com

    House Democrats fail to curb Trump conflict powers on Iran as GOP holds agency | Invesloan.com

    Rep. Pramila Jayapal says she faces dying threats over Cuba diplomacy journey | Invesloan.com

    Jim Jordan confronts Fairfax prosecutor over soft-on-crime insurance policies | Invesloan.com

    Wisconsin official says FBI agent visited election director at her house | Invesloan.com

    Cooper faces soft-on-crime claims from critics forward of NC Senate race | Invesloan.com

    House committee report says Walz enabled billions in Minnesota fraud | Invesloan.com

    Federal probe seeks to seek out if taxpayers footing the invoice when detransitioners sue | Invesloan.com

    Miss. Gov. Reeves cancels redistricting session, GOP House bid stalls | Invesloan.com

    LATEST NEWS

    The bond market is already mountaineering charges as Kevin Warsh takes over as Fed’s new chair | Invesloan.com

    May 14, 2026

    Supreme Court leaves telehealth abortion capsule entry intact for now | Invesloan.com

    May 14, 2026

    OpenAI’s Codex on Mobile Is Good News for Open-Laptop Walkers | Invesloan.com

    May 14, 2026

    HCW Biologics GAAP EPS of $0.37 beats by $0.81, income of $6.53M | Invesloan.com

    May 14, 2026
    POPULAR

    China’s first passenger jet completes maiden commercial flight

    May 28, 2023

    Numbers taking US accountancy exams drop to lowest level in 17 years

    May 29, 2023

    Toyota chair faces removal vote over governance issues

    May 29, 2023
    Advertisement
    Load WordPress Sites in as fast as 37ms!
    Facebook Twitter Pinterest WhatsApp Instagram
    © 2007-2023 Invesloan.com All Rights Reserved.
    • Privacy
    • Terms
    • Press Release
    • Advertise
    • Contact

    Type above and press Enter to search. Press Esc to cancel.

    invesloan.com
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    • Manage options
    • Manage services
    • Manage {vendor_count} vendors
    • Read more about these purposes
    View preferences
    • {title}
    • {title}
    • {title}